Istergan

Entecavir, the active ingredient in Istergan, is an antiviral presented as an oral tablet for oral use. It is indicated for the treatment of chronic hepatitis B infection in adults and children with compensated liver disease. The medication works by inhibiting the viral DNA polymerase, thereby reducing viral replication and disease progression.

GNH USA supplies Istergan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Entecavir is an antiviral medication used primarily in the management of hepatitis B virus (HBV) infection. Chronic hepatitis B infection: reduces HBV DNA levels, improves liver enzyme profiles, and helps prevent progression to cirrhosis or liver cancer. Compensated liver disease due to hepatitis B: maintains hepatic function and reduces the risk of decompensation. HBV carriers (asymptomatic): lowers viral replication to decrease transmission risk and long‑term liver damage.

Entecavir may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: mild to moderate tiredness reported by some patients. - Headache: occasional tension‑type headaches. - Nausea: transient stomach upset, often resolves with continued therapy. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Lactic acidosis: rare metabolic complication requiring immediate medical attention. - Severe allergic reaction: includes rash, swelling, or anaphylaxis. - Hepatic decompensation: worsening liver function in patients with advanced disease.

When prescribing entecavir, clinicians should consider several precautionary measures to ensure safe use. Liver function monitoring: Regularly assess ALT and AST levels to detect hepatic changes. Renal function assessment: Evaluate creatinine clearance before initiating therapy, especially in patients with impaired kidneys. History of lactic acidosis: Use with caution in individuals with prior metabolic disorders. Avoid concurrent nucleoside analogues: Combining with similar agents may increase toxicity risk. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Entecavir may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Co‑administration with other nucleos(t)ide analogues: may increase risk of mitochondrial toxicity. - Combination with interferon therapy: can heighten adverse event profile.

Moderate Interactions (Monitor Closely): - Use with nephrotoxic drugs: may necessitate dose adjustment of entecavir. - Concurrent immunosuppressants: monitor for HBV reactivation. - Oral contraceptives: potential reduction in contraceptive efficacy, advise additional protection.